



**Supplemental Figure 1.** Kaplan-Meier curves for overall survival or progression-free survival based on the criteria of 30% tumor size reduction and 50% reduction of maximum standardized uptake value (SUVmax) (A, B) or 60% reduction of total lesion glycolysis at SUV of 2.5 (TLG2.5) (C, D). The responses are calculated using targetable lesions, defined by the Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1).

**Supplemental Table 1.** Characteristics of measurable lesions from all patients  
(lesion number=620)

| <b>Characteristics</b>            | <b>No. (%)</b>     |
|-----------------------------------|--------------------|
| Histologic type                   |                    |
| Adenocarcinoma                    | 516 (83.2)         |
| Poorly cohesive carcinoma         | 104 (16.8)         |
| Differentiation (n=516)           |                    |
| Well to moderate                  | 301 (58.3)         |
| Poor                              | 215 (41.7)         |
| HER2 status                       |                    |
| Negative                          | 456 (73.5)         |
| Positive                          | 164 (26.5)         |
| Site                              |                    |
| Primary lesions                   | 4 (0.6)            |
| Metastatic lesions                |                    |
| Lymph node                        | 324 (52.3)         |
| Liver                             | 262 (42.3)         |
| Bone                              | 11 (1.8)           |
| Peritoneal seeding nodule         | 9 (1.5)            |
| Adrenal gland                     | 5 (0.8)            |
| Adnexa of uterus                  | 4 (0.6)            |
| Soft tissue                       | 1 (0.2)            |
| Median size of lesion (range, mm) | 15.2 (10.0- 131.3) |
| Median SUVmax (range)             | 9.4 (0.0- 38.9)    |
| Median TLG2.5 (range)             | 31.4 (0.0- 3481.9) |

HER2, human epidermal growth factor receptor 2; SUVmax, maximum standardized uptake value; TLG2.5, total lesion glycolysis at SUV of 2.5

**Supplemental Table 2.** Multivariate Cox proportional analyses of size and SUVmax reduction for overall survival and progression-free survival

| Variable                                 | n  | Overall survival |            |          | Progression-free survival |            |          |
|--|----|------------------|------------|----------|---------------------------|------------|----------|
|  |    | HR               | 95% CI     | <i>p</i> | HR                        | 95% CI     | <i>p</i> |
| <b>Age</b>                               |    |                  |            |          |                           |            |          |
| < 60yrs                                  | 36 | 1                |            |          | 1                         |            |          |
| ≥60 yrs                                  | 38 | 1.19             | 0.57- 2.49 | 0.638    | 1.10                      | 0.60- 2.02 | 0.751    |
| <b>Histologic type</b>                   |    |                  |            |          |                           |            |          |
| Adenocarcinoma                           | 59 | 1                |            |          | 1                         |            |          |
| Poorly cohesive carcinoma                | 15 | 1.36             | 0.61- 3.05 | 0.454    | 1.02                      | 0.49- 2.14 | 0.954    |
| <b>HER2</b>                              |    |                  |            |          |                           |            |          |
| Negative                                 | 60 | 1                |            |          | 1                         |            |          |
| Positive                                 | 14 | 1.61             | 0.30- 1.61 | 0.301    | 1.22                      | 0.58- 2.60 | 0.599    |
| <b>Previous gastrectomy</b>              |    |                  |            |          |                           |            |          |
| Yes                                      | 21 | 1                |            |          | 1                         |            |          |
| No                                       | 53 | 3.38             | 1.38- 8.31 | 0.008    | 3.04                      | 1.41- 6.55 | 0.005    |
| <b>30% size and 50% SUVmax reduction</b> |    |                  |            |          |                           |            |          |
| Yes                                      | 36 | 1                |            |          | 1                         |            |          |
| No                                       | 38 | 4.41             | 1.98- 9.83 | <0.001   | 2.58                      | 1.40- 4.77 | 0.002    |

HR, hazard ratio; CI, confidence interval

**Supplemental Table 3.** Multivariate Cox proportional analyses of size and TLG2.5 reduction for overall survival and progression-free survival

| Variable                          | n  | Overall survival |            |          | Progression-free survival |            |          |
|-----------------------------------|----|------------------|------------|----------|---------------------------|------------|----------|
|                                   |    | HR               | 95% CI     | <i>p</i> | HR                        | 95% CI     | <i>p</i> |
| Age                               |    |                  |            |          |                           |            |          |
| < 60yrs                           | 35 | 1                |            |          | 1                         |            |          |
| ≥60 yrs                           | 36 | 1.25             | 0.58- 2.69 | 0.562    | 1.10                      | 0.59- 2.05 | 0.773    |
| Histologic type                   |    |                  |            |          |                           |            |          |
| Adenocarcinoma                    | 58 | 1                |            |          | 1                         |            |          |
| Poorly cohesive carcinoma         | 13 | 1.87             | 0.79- 4.44 | 0.156    | 1.00                      | 0.45- 2.25 | 0.994    |
| HER2                              |    |                  |            |          |                           |            |          |
| Negative                          | 57 | 1                |            |          | 1                         |            |          |
| Positive                          | 14 | 1.27             | 0.54- 2.97 | 0.585    | 1.07                      | 0.51- 2.22 | 0.860    |
| Previous gastrectomy              |    |                  |            |          |                           |            |          |
| Yes                               | 20 | 1                |            |          | 1                         |            |          |
| No                                | 51 | 2.88             | 1.23- 6.76 | 0.015    | 2.91                      | 1.31- 6.50 | 0.009    |
| 30% size and 60% TLG2.5 reduction |    |                  |            |          |                           |            |          |
| Yes                               | 43 | 1                |            |          | 1                         |            |          |
| No                                | 28 | 3.87             | 1.77- 8.45 | 0.001    | 2.19                      | 1.16- 4.14 | 0.015    |